Continued B-cell aplasia and subsequent hypogammaglobulinemia are linked to CD19-CAR performance and persistence, which is dependent on the product that was used for the treatment of the underlying disease [131,139]. The gene discussed is CD19; the disease is agammaglobulinemia.